This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CDP 870, CDP870, certolizumab pegol
Description: Cimzia is a high-affinity humanized pegylated monoclonal antibody fragment that binds to human TNF-alpha, a key pro-inflammatory cytokine with a central role in inflammatory processes. Binding to membrane-associated and soluble TNF-alpha neutralizes the cytokine.
Certolizumab pegol does not contain a fragment crystallizable (Fc) region, which is normally present in a complete antibody, and therefore does not fix complement or cause antibody-dependent cell-mediated cytotoxicity in vitro. It does not induce apoptosis in vitro in human peripheral blood-derived monocytes or lymphocytes, nor does certolizumab pegol induce neutrophil degranulation.
Deal Structure: Cimzia was created using the license of XOMA's Bacterial Cell Expression (BCE) technology. XOMA will receive a royalty on worldwide sales of Cimzia. In August 2010, XOMA sold its royalty interest in Cimzia for $4 million to an undisclosed buyer.
Enzon and Nektar
Under Enzon's agreement with Nektar, itwill share a portion of Nektar's royalties on Cimzia.
Nektar and Celltech
Nektar entered into a license, manufacturing and supply agreement for Cimzia with Celltech Group plc in 2000. This agreement was subsequently assigned to Pharmacia for the rheumatoid arthritis indication. In April 2003, Pfizer Inc acquired Pharmacia and in February 2004, Pfizer Inc reassigned Cimzia rights back to Celltech.
Celltech and UCB
In 2004, Celltech was acquired by UCB Pharma.
UCB and PDL
PDL BioPharma entered into patent license agreements with numerous companies that are independently developing humanized antibodies, including UCB Group. In each license...See full deal structure in Biomedtracker
Partners: Royalty Pharma AG Enzon Pharmaceuticals, Inc. Astellas Pharma, Inc. Nektar Therapeutics NewBridge Pharmaceuticals Dermira Inc.
Additional information available to subscribers only: